Results 291 to 300 of about 349,023 (332)

A Practical Approach to Implementing ICH Q14: Tools for Analytical Quality by Design in Capillary Electrophoresis Method Development

ELECTROPHORESIS, EarlyView.
ABSTRACT The ICH Q14 guideline introduces a structured framework for analytical method development based on Analytical Quality by Design (AQbD) principles, aiming to ensure robust, reliable, and fit‐for‐purpose methods throughout the product lifecycle.
Ewoud van Tricht, Cari E. Sänger ‐ van de Griend   +1 more
wiley   +1 more source

Differentiating Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Responses Between Infection and Vaccination: Challenges for Epidemiological Research. [PDF]

J Infect Dis
Nayagam SN, Coote W, Carroll MTC, Toh ZQ, Licciardi PV, Abramson MJ, Walker-Bone K, Lane TJ.   +7 more
europepmc   +1 more source

Exploring the long‐term effects of COVID‐19 in patients with epilepsy: A multicenter Italian observational study

Epilepsia Open, EarlyView.
Abstract Objective Coronavirus disease‐19 (COVID‐19), caused by SARS‐CoV‐2, has led to a global pandemic since December 2019. People with epilepsy (PwE) face higher risks of severe COVID‐19 outcomes and may be more vulnerable to long‐term neurological and psychiatric effects. Methods This multicenter, retrospective cohort study reviewed medical records
Fedele Dono, Mirella Russo, Giacomo Evangelista, Clarissa Corniello, Claudio Liguori, Carmen Calvello, Flavia Narducci, Catello Vollono, Stefano Sensi   +8 more
wiley   +1 more source

Advances and Prospects of Fowl Adenoviruses Vaccine Technologies in the Past Decade. [PDF]

Int J Mol Sci
Zhu C, Yang P, Zhou J, Liu X, Huang Y, Wan C.   +5 more
europepmc   +1 more source

Development of a Promising Bivalent Vaccine Against Klebsiella pneumoniae Based on Glycoengineered GMMA (geGMMA)

Exploration, EarlyView.
Multidrug‐resistant Klebsiella pneumoniae poses a significant threat as a nosocomial pathogen, with no current licensed vaccines available. This study used a mutant E. coli strain expressing exogenous polysaccharides (from K. pneumoniae) to establish glycoengineered generalized modules for membrane antigens (geGMMA) vaccine platform, which demonstrated
Jingqin Ye, Wenhua Huang, Shujuan Yu, Yan Guo, Peng Sun, Ziyuan Chen, Linhui Hao, Yan Zhang, Caixia Li, Yongqiang Jiang, Jun Wu, Li Zhu, Hengliang Wang, Chao Pan   +13 more
wiley   +1 more source

Exploring the Potential and Advancements of Circular RNA Therapeutics

Exploration, EarlyView.
Given the remarkable advantages in terms of stability, sustained expression profile, safety, wide range of druggable targets, scalable and cost‐effective manufacturing capabilities, circRNA is currently undergoing intensive investigation for various therapeutic applications such as vaccines, protein replacement, genetic disease treatment, gene therapy,
Lei Wang, Lianqing Wang, Chunbo Dong, Jialong Liu, Guoxin Cui, Shan Gao, Zhida Liu   +6 more
wiley   +1 more source

Schmallenberg virus epidemiology and regional control strategies: diagnostics, vaccines, and vector management. [PDF]

Front Cell Infect Microbiol
Wang J, Jia Q, Xiang H, Wang F, Sun C, Chang J, Jiang Z, Yin X.   +7 more
europepmc   +1 more source

Extracellular Vesicle‐Based mRNA Therapeutics and Vaccines

Exploration, EarlyView.
This review provides a comprehensive analysis of recent advancements in extracellular vesicle (EV)‐based messenger RNA (mRNA) applications for therapeutics and vaccines. It systematically outlines strategies for mRNA encapsulation within EVs and elucidates the challenges associated with this technology, offering insights into future research directions
Qi Li, Haonan Xing, Abid Naeem, Kaiyue Zhang, Aiping Zheng, Yuanyu Huang, Mei Lu   +6 more
wiley   +1 more source

Innate Immune Response to Powassan Virus Infection: Progress Toward Infection Control. [PDF]

Vaccines (Basel)
Kayesh MEH, Kohara M, Tsukiyama-Kohara K.   +2 more
europepmc   +1 more source

Adaptation of the Vaccine Prophylaxis Strategy to Variants of the SARS-CoV-2 Virus. [PDF]

Vaccines (Basel)
Gulova SM, Veselkina US, Astrakhantseva IV.   +2 more
europepmc   +1 more source